Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 4,170 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Clear all
Completed Phase 2 Interventional Results available

Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study

NCT02967458
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Perflutren Lipid Microsphere Intravenous Suspension
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional

Low-Count Quantitative SPECT for Men Treated With Radium-223

NCT07221825
View directory record Official record
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional

The Florida ASCENT Study

NCT07042243
View directory record Official record
Conditions
Cancer, Food Deprivation, Food Habits, Food Selection, Colorectal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Gynecologic Cancer, Hematologic Cancer, Skin Cancer, Melanoma, Nutrition Poor, Nutritional Deficiency
Interventions
MyCarePulse and ASCENT PN
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting Not applicable Interventional

MRI for Assessing Prostate Cancer Response

NCT01607008
View directory record Official record
Conditions
Prostate Cancer
Interventions
MRI imaging
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 2 Interventional Results available

Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer

NCT00551525
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiotherapy, Samarium 153
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
29
States / cities
Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 25, 2026, 1:10 PM EDT
Suspended Phase 2 Interventional

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer

NCT04346225
View directory record Official record
Conditions
Prostate Cancer, Advanced Prostate Carcinoma
Interventions
Hyperpolarized C13, Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
Ivan de Kouchkovsky, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting No phase listed Observational

Stone and Laser Therapies Post-Market Study (SALT)

NCT06982235
View directory record Official record
Conditions
Benign Prostate Hypertrophy(BPH), Renal Calculi, Ureteral Stones, Kidney Stones, Calculi, Urinary, Urinary Tract Procedure
Interventions
Ureteroscope system, Laser system
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Phoenix, Arizona • Miami, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

NCT01994590
View directory record Official record
Conditions
Prostate Cancer
Interventions
Dovitinib, Abiraterone Acetate, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting Not applicable Interventional

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer

NCT03697148
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Multiparametric Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Scottsdale, Arizona • New Haven, Connecticut + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

NCT02262455
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Endometrial Cancer, Solid Tumors
Interventions
STM 434, Liposomal doxorubicin
Drug
Lead sponsor
Santa Maria Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2017 · Synced Oct 25, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer

NCT00450008
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
GM-CSF, thalidomide, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

NCT03972657
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions
REGN5678, Cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
24
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Not applicable Interventional

Feasibility Study: Educational Genetic Test Video

NCT06166758
View directory record Official record
Conditions
Prostate Cancer, Education
Interventions
Educational Video
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational

African Cancer Genome: GMD

NCT05754658
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer
Interventions
Standard of Care
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting No phase listed Observational

Microendoscopic EI Sensing for Real-time Intraoperative Surgical Margin Assessment

NCT06039085
View directory record Official record
Conditions
Prostate Cancer
Interventions
custom device to demonstrate a significant difference in electrical impedance signatures
Device
Lead sponsor
Ryan J. Halter
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Terminated Phase 2 Interventional Results available

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

NCT05960578
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Interventions
Apalutamide, Biopsy, Biospecimen Collection, Computed Tomography, Golimumab, Magnetic Resonance Imaging, PSMA PET Scan, Bone Scan
Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Completed Phase 1 Interventional

AZD8186 First Time In Patient Ascending Dose Study

NCT01884285
View directory record Official record
Conditions
Advanced Castrate-resistant Prostate Cancer CRPC, Squamous Non-Small Cell Lung Cancer sqNSCLC, Triple Negative Breast Cancer TNBC
Interventions
Part A: AZD8186 monotherapy, Part B: AZD8186 monotherapy, Part C1: Abiraterone acetate combination with AZD8186, Part D1: AZD2014 combination with AZD8186, Part D2 AZD2014 combination with AZD8186, Part C2: Abiraterone acetate combination with AZD8186
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
5
States / cities
Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Not applicable Interventional

Multilevel Intervention for Precision Oncology

NCT06825715
View directory record Official record
Conditions
Advanced Cancers of the Prostate, Cancers of the Lung
Interventions
Multilevel intervention
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
2,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional

The University of Miami Adapt (UAdapt) Trial

NCT06111313
View directory record Official record
Conditions
Prostate Cancer
Interventions
FTLEAD, Ultra-Short-Term Androgen Deprivation Therapy with Relugolix, HypoLEAD, ADT Standard of Care
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 85 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Not listed Not applicable Interventional

Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer

NCT01562223
View directory record Official record
Conditions
Prostate Cancer
Interventions
motexafin gadolinium
Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 25, 2026, 1:10 PM EDT
Completed No phase listed Observational

To Explore Racial Differences in Potential Risk Factors for Developing Prostate Cancer in the VA Population.

NCT00007579
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years to 74 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2008 · Synced Oct 25, 2026, 1:10 PM EDT
Active, not recruiting Not applicable Interventional

Rectal Spacers Use in Prostate Cancer Radiation Therapy

NCT06594887
View directory record Official record
Conditions
Prostate Cancer
Interventions
SpaceOAR Vue, BioProtect Balloon Implant System
Device
Lead sponsor
Princeton ProCure management, LLC.
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 25, 2026, 1:10 PM EDT
Recruiting Phase 3 Interventional

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

NCT05939414
View directory record Official record
Conditions
Oligometastatic Prostate Cancer (OMPC)
Interventions
AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
39
States / cities
Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 1:10 PM EDT